Terms: = Kidney tumors AND ERG, P11308, 2078 AND Treatment
4 results:
1. Targetable gene fusions and aberrations in genitourinary oncology.
Pederzoli F; Bandini M; Marandino L; Ali SM; Madison R; Chung J; Ross JS; Necchi A
Nat Rev Urol; 2020 Nov; 17(11):613-625. PubMed ID: 33046892
[TBL] [Abstract] [Full Text] [Related]
2. Aberrant expression of neuroendocrine markers in angiosarcoma: a potential diagnostic pitfall.
Tessier Cloutier B; Costa FD; Tazelaar HD; Folpe AL
Hum Pathol; 2014 Aug; 45(8):1618-24. PubMed ID: 24846674
[TBL] [Abstract] [Full Text] [Related]
3. Pazopanib for the first-line treatment of patients with advanced and/or metastatic renal cell carcinoma : a NICE single technology appraisal.
Kilonzo M; Hislop J; Elders A; Fraser C; Bissett D; McClinton S; Mowatt G; Vale L
Pharmacoeconomics; 2013 Jan; 31(1):15-24. PubMed ID: 23329590
[TBL] [Abstract] [Full Text] [Related]
4. Everolimus for the second-line treatment of advanced and/or metastatic renal cell cancer: a critique of the submission from Novartis.
Pitt M; Crathorne L; Moxham T; Bond M; Hyde C
Health Technol Assess; 2010 Oct; 14(Suppl. 2):41-6. PubMed ID: 21047490
[TBL] [Abstract] [Full Text] [Related]
